Quest Diagnostics Inc
XMUN:QDI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Q
|
Quest Diagnostics Inc
XMUN:QDI
|
US |
|
Bank Handlowy w Warszawie SA
F:6HW
|
PL |
Quest Diagnostics Inc
Quest Diagnostics is one of the largest clinical laboratory companies in the United States. It runs labs and patient service centers that collect and analyze blood, urine, and other samples for doctors, hospitals, health plans, employers, and consumers. The company helps answer a basic medical question: what is going on inside the body and what treatment should come next. It makes money by charging for diagnostic tests and related lab services. Most of its work comes from physicians and healthcare systems ordering routine blood work, disease screening, and more specialized tests, plus from employer and consumer testing programs. Quest also supports health plans and drug developers with testing, data, and other laboratory services. What makes Quest different is its role in the healthcare supply chain. It is not a drug maker or a hospital; it sits between the doctor and the diagnosis, turning samples into information that guides care. That makes its business tied to everyday medical testing, which gives it a steady place in the healthcare system.
Quest Diagnostics is one of the largest clinical laboratory companies in the United States. It runs labs and patient service centers that collect and analyze blood, urine, and other samples for doctors, hospitals, health plans, employers, and consumers. The company helps answer a basic medical question: what is going on inside the body and what treatment should come next.
It makes money by charging for diagnostic tests and related lab services. Most of its work comes from physicians and healthcare systems ordering routine blood work, disease screening, and more specialized tests, plus from employer and consumer testing programs. Quest also supports health plans and drug developers with testing, data, and other laboratory services.
What makes Quest different is its role in the healthcare supply chain. It is not a drug maker or a hospital; it sits between the doctor and the diagnosis, turning samples into information that guides care. That makes its business tied to everyday medical testing, which gives it a steady place in the healthcare system.
Strong quarter: Quest said first-quarter revenue rose 9.2% to $2.9 billion and adjusted EPS increased about 13%, driven mainly by broad-based organic growth and higher test mix.
Guidance raised: Management lifted full-year 2026 revenue and EPS guidance after the strong start to the year, and still expects operating margin expansion.
Growth drivers: Performance was strong across physician, hospital, and consumer channels, with especially notable strength in advanced diagnostics, consumer health partnerships, and the Corewell and Fresenius collaborations.
Cost and productivity: The company said automation and AI helped drive productivity gains, while Project Nova remains a multiyear investment that will weigh on 2026 EPS by $0.25.
Macro watchpoints: Management said weather created some short-term noise, fuel costs are being absorbed into guidance, and it has not seen a meaningful ACA subsidy impact so far.
Strategic momentum: Quest highlighted continued investment in brain health, oncology, and other advanced tests, while also pointing to new partnerships and continued M&A interest.
